Valuation dashboard for Contineum Therapeutics, Inc. (CTNM) with P/E N/A, P/B 2.04, EV/EBITDA -9.40 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $13.76, CTNM has negative trailing earnings (P/E not meaningful) and an ROE of -24.73%. Market capitalisation stands at $518M.
Balance sheet quality for CTNM: current ratio of 27.5. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 2.04 |
| EV / EBITDA | -9.40 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $2.40 |
| vs Current Price | -82.6% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CTNM | Contineum Therapeutics, Inc. | $518M | 2.04 | -24.7% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $13.76 |
| Market Cap | $518M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -24.73% |
| Return on Invested Capital | -26.96% |
| Return on Assets | -22.99% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACIU · ALDX · AMRN · ANRO · CADL · CAPR · KYTX
Explore sector: Healthcare · Biotechnology
More sections of CTNM: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks